These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 25837922

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, Miyoshi T, Hirata K, Yoshikawa J, Ito H, FESC, for Effect of a DPP-4 inhibitor on left ventricular diastolic dysfunction in patients with type 2 diabetes and diabetic cardiomyopathy (3D) study investigators.
    Cardiovasc Diabetol; 2015 Jun 19; 14():83. PubMed ID: 26084668
    [Abstract] [Full Text] [Related]

  • 4. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.
    Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, Gilbert RE.
    Cardiovasc Ther; 2013 Oct 19; 31(5):259-67. PubMed ID: 22963483
    [Abstract] [Full Text] [Related]

  • 5. Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.
    Zhang X, Zhang Z, Yang Y, Suo Y, Liu R, Qiu J, Zhao Y, Jiang N, Liu C, Tse G, Li G, Liu T.
    Cardiovasc Diabetol; 2018 Dec 27; 17(1):160. PubMed ID: 30591063
    [Abstract] [Full Text] [Related]

  • 6. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
    Tang ST, Su H, Zhang Q, Tang HQ, Wang CJ, Zhou Q, Wei W, Zhu HQ, Wang Y.
    Int J Mol Med; 2016 Jun 27; 37(6):1558-66. PubMed ID: 27122056
    [Abstract] [Full Text] [Related]

  • 7. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
    Ramírez E, Picatoste B, González-Bris A, Oteo M, Cruz F, Caro-Vadillo A, Egido J, Tuñón J, Morcillo MA, Lorenzo Ó.
    Cardiovasc Diabetol; 2018 Jan 11; 17(1):12. PubMed ID: 29325553
    [Abstract] [Full Text] [Related]

  • 8. Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
    Al-Damry NT, Attia HA, Al-Rasheed NM, Al-Rasheed NM, Mohamad RA, Al-Amin MA, Dizmiri N, Atteya M.
    Biomed Pharmacother; 2018 Nov 11; 107():347-358. PubMed ID: 30099338
    [Abstract] [Full Text] [Related]

  • 9. Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease.
    Beraldo JI, Benetti A, Borges-Júnior FA, Arruda-Junior DF, Martins FL, Jensen L, Dariolli R, Shimizu MH, Seguro AC, Luchi WM, Girardi ACC.
    Int J Mol Sci; 2019 Apr 20; 20(8):. PubMed ID: 31010001
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
    Karabulut S, Coskun ZM, Bolkent S.
    Pharmacol Rep; 2015 Oct 20; 67(5):846-53. PubMed ID: 26398375
    [Abstract] [Full Text] [Related]

  • 11. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP.
    Circ Cardiovasc Imaging; 2014 Mar 20; 7(2):274-81. PubMed ID: 24503784
    [Abstract] [Full Text] [Related]

  • 12. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction.
    Esposito G, Cappetta D, Russo R, Rivellino A, Ciuffreda LP, Roviezzo F, Piegari E, Berrino L, Rossi F, De Angelis A, Urbanek K.
    Br J Pharmacol; 2017 Nov 20; 174(22):4070-4086. PubMed ID: 27922176
    [Abstract] [Full Text] [Related]

  • 13. Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia-reperfusion injury in rats with diabetes mellitus type 2.
    Bradic J, Milosavljevic I, Bolevich S, Litvitskiy PF, Jeremic N, Bolevich S, Zivkovic V, Srejovic I, Jeremic J, Jovicic N, Mitrovic S, Jakovljevic V.
    Clin Exp Pharmacol Physiol; 2021 Apr 20; 48(4):575-584. PubMed ID: 33352623
    [Abstract] [Full Text] [Related]

  • 14. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
    Gonçalves A, Marques C, Leal E, Ribeiro CF, Reis F, Ambrósio AF, Fernandes R.
    Biochim Biophys Acta; 2014 Sep 20; 1842(9):1454-63. PubMed ID: 24769045
    [Abstract] [Full Text] [Related]

  • 15. Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats.
    Alves BEO, de Alencar AKN, Gamba LER, Trachez MM, da Silva JS, Araújo JSC, Montagnoli TL, Mendes LVP, Pimentel-Coelho PM, do M N Cunha V, Mendez-Otero R, Oliveira GMM, Lima LM, Barreiro EJ, Sudo RT, Zapata-Sudo G.
    Pharmacol Rep; 2019 Dec 20; 71(6):1190-1200. PubMed ID: 31669883
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
    Fukui K, Kawahito H, Wakana N, Kikai M, Terada K, Yamamoto K, Irie D, Kato T, Miyagawa S, Yamada H.
    J Renin Angiotensin Aldosterone Syst; 2015 Dec 20; 16(4):1001-9. PubMed ID: 26195265
    [Abstract] [Full Text] [Related]

  • 17. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
    Zhou Y, Wang H, Man F, Guo Z, Xu J, Yan W, Li J, Pan Q, Wang W.
    Cardiovasc Drugs Ther; 2018 Dec 20; 32(6):541-552. PubMed ID: 30328028
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes.
    Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, Murohara T.
    Am J Physiol Heart Circ Physiol; 2013 Aug 01; 305(3):H295-304. PubMed ID: 23709595
    [Abstract] [Full Text] [Related]

  • 19. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.
    dos Santos L, Salles TA, Arruda-Junior DF, Campos LC, Pereira AC, Barreto AL, Antonio EL, Mansur AJ, Tucci PJ, Krieger JE, Girardi AC.
    Circ Heart Fail; 2013 Sep 01; 6(5):1029-38. PubMed ID: 23894014
    [Abstract] [Full Text] [Related]

  • 20. Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.
    Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mahmoud AM.
    Drug Des Devel Ther; 2016 Sep 01; 10():2095-107. PubMed ID: 27418808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.